PP_1170x120_10-25-21

Dan Kistner

Vizient analysis shows prices for existing drugs spike after approval

Vizient analysis shows prices for existing drugs spike after approval

IRVING, Texas — Analysis by Vizient of four drugs that have been consistently used in hospitals in some cases for more than 50 years, shows manufacturers are choosing to take significant price increases after receiving formal approval by the Food and Drug Administration (FDA). The effect is an estimated $20.25 billion increase in U.S. health

Vizient identifies essential medications in hospitals, highlights fragility of the supply chain

Vizient identifies essential medications in hospitals, highlights fragility of the supply chain

IRVING, Texas — Vizient has identified 200 essential medications whose absence may threaten hospitals’ ability to provide immediate and high quality patient care, including 77 acute and chronic life-saving drugs that have no alternatives in the event of a supply disruption. The medications designated as essential with no alternatives include vital chemotherapy drugs and life-saving reversal agents such